Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis

Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability. Here, we report the case of a 30-year-old patient with multiple sclerosis receiving natalizumab as monotherapy who subsequentl...

Descrición completa

Detalles Bibliográficos

Principais autores:	Marina Rodrigues Lima, Luis Arthur Brasil Gadelha Farias, Maycon Fellipe da Ponte, Luís Edmundo Teixeira de Arruda Furtado
Formato:	Artigo
Idioma:	Inglês
Publicado:	SMC MEDIA SRL 2019-02-01
Series:	European Journal of Case Reports in Internal Medicine
Assuntos:	Infection viruses cytomegalovirus natalizumab multiple sclerosis
Acceso en liña:	https://www.ejcrim.com/index.php/EJCRIM/article/view/1046
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!